



## Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Alejandra González-Duarte<sup>1</sup> · John L. Berk<sup>2</sup> · Dianna Quan<sup>3</sup> · Michelle L. Mauermann<sup>4</sup> · Hartmut H. Schmidt<sup>5</sup> · Michael Polydefkis<sup>6</sup> · Márcia Waddington-Cruz<sup>7</sup> · Mitsuharu Ueda<sup>8</sup> · Isabel M. Conceição<sup>9</sup> · Arnt V. Kristen<sup>10</sup> · Teresa Coelho<sup>11</sup> · Cécile A. Cauquil<sup>12</sup> · Céline Tard<sup>13</sup> · Madeline Merkel<sup>14</sup> · Emre Aldinc<sup>14</sup> · Jihong Chen<sup>14</sup> · Marianne T. Sweetser<sup>14</sup> · Jing Jing Wang<sup>14</sup> · David Adams<sup>15</sup>

Published online: 7 February 2020  
© The Author(s) 2020

**Correction to: Journal of Neurology**  
<https://doi.org/10.1007/s00415-019-09602-8>

The original version of this article unfortunately contained a mistake in Table 1.

Units for albumin were given as g/dL. It should be g/L.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

---

The original article can be found online at <https://doi.org/10.1007/s00415-019-09602-8>.

---

✉ Alejandra González-Duarte  
gonzalezduarte@aol.com

<sup>1</sup> Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, CdMx, CP 01400 México City, Mexico

<sup>2</sup> Boston Medical Center, Boston, MA, USA

<sup>3</sup> University of Colorado, Denver, CO, USA

<sup>4</sup> Mayo Clinic, Rochester, MN, USA

<sup>5</sup> University of Münster, Münster, Germany

<sup>6</sup> Johns Hopkins University School of Medicine, Baltimore, MD, USA

<sup>7</sup> Hospital Universitário Clementino Fraga Filho-UFRJ, Rio de Janeiro, Brazil

<sup>8</sup> Kumamoto University Hospital, Kumamoto, Japan

<sup>9</sup> CHULN, Hospital de Santa Maria and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

<sup>10</sup> University of Heidelberg, Heidelberg, Germany

<sup>11</sup> Hospital de Santo António, Centro Hospitalar Universitário Do Porto, Porto, Portugal

<sup>12</sup> AP-HP Université Paris Saclay, CHU Bicêtre, Le Kremlin Bicêtre, France

<sup>13</sup> Université de Lille, Lille, France

<sup>14</sup> Alnylam Pharmaceuticals, Cambridge, MA, USA

<sup>15</sup> AP-HP, Université Paris Saclay, CHU Bicêtre, Université Paris-Sud, INSERM 1195, Paris, France

**Table 1** Disease characteristics of autonomic endpoints at baseline

Characteristic	Placebo ( <i>n</i> = 77)	Patisiran ( <i>n</i> = 148)	Total ( <i>n</i> = 225)
COMPASS-31 total score (range 0–100), mean ( $\pm$ SD)	30.3 (16.4)	30.6 (17.6)	30.5 (17.1)
Orthostatic intolerance (range: 0–40), mean ( $\pm$ SD)	13.2 (11.2)	14.2 (10.8)	13.8 (10.9)
Vasomotor (range 0–5), mean ( $\pm$ SD)	1.0 (1.4)	0.9 (1.44)	1.0 (1.4)
Secretomotor (range 0–15), mean ( $\pm$ SD)	4.9 (3.7)	4.2 (3.7)	4.4 (3.7)
Gastrointestinal (range 0–25), mean ( $\pm$ SD)	8.1 (3.5)	8.2 (4.3)	8.1 (4.1)
Bladder (range 0–10), mean ( $\pm$ SD)	1.9 (2.7)	2.0 (2.5)	2.0 (2.5)
Pupillomotor (range 0–5), mean ( $\pm$ SD)	1.1 (1.1)	1.2 (1.2)	1.2 (1.2)
mBMI ( $\text{kg}/\text{m}^2 \times \text{g}/\text{L}$ ), mean ( $\pm$ SD)	989.9 (214.2)	969.7 (210.5)	976.6 (211.5)
BMI ( $\text{kg}/\text{m}^2$ ), mean ( $\pm$ SD)	23.6 (4.3)	23.0 (4.4)	23.2 (4.4)
Albumin (g/L), mean ( $\pm$ SD)	41.8 (3.4)	42.1 (3.5)	42.0 (3.5)
Weight (kg), mean ( $\pm$ SD)	67.5 (15.7)	67.3 (16.6)	67.4 (16.3)
mNIS + 7 total score (range 0–304), mean ( $\pm$ SD)	74.6 (37.0)	80.9 (41.5)	78.8 (40.1)
Postural blood pressure (range 0–2), mean ( $\pm$ SD)	0.6 (0.7)	0.7 (0.8)	0.6 (0.8)
Norfolk QOL-DN total score (range –4 to 136), mean ( $\pm$ SD)	55.5 (24.3)	59.6 (28.2)	58.3 (27.0)
Autonomic neuropathy domain (range 0–12), mean ( $\pm$ SD)	2.9 (2.9)	3.0 (2.8)	3.0 (2.8)

*BMI* body mass index, *COMPASS-31* Composite Autonomic Symptom Score-31, *mBMI* modified body mass index, *mNIS + 7* modified Neuropathy Impairment Score + 7, *Norfolk QOL-DN* Norfolk Quality of Life-Diabetic Neuropathy